CStone Pharmaceuticals Announced The IND Approval Of CS5001, A Potential Global Best-in-class ROR1-targeting ADC By The U.S. Food And Drug Administration

By PR Newswire SUZHOU, China, Jan. 2, 2022 /PRNewswire/ — CStone Pharmaceuticals (“CStone”, HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the investigational new drug (IND) application of CS5001, a potential global best-in-class antibody-drug conjugate (ADC) targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1) has received a STUDY MAY PROCEED (SMP) letter from the U.S. Food and Drug Administration (FDA). CS5001 will commence in the cl…

Read More